PET Radiopharmaceuticals in Oncology Beyond FDG
Several imaging modalities to diagnose cancer, which include computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, optical imaging, and gamma scintigraphy, have been previously used. For instance, CT and MRI provide considerable anatomic
- PDF / 12,857,797 Bytes
- 245 Pages / 439.42 x 683.15 pts Page_size
- 66 Downloads / 185 Views
123
Personalized Pathway-Activated Systems Imaging in Oncology
Tomio Inoue • David Yang • Gang Huang Editors
Personalized Pathway- Activated Systems Imaging in Oncology Principal and Instrumentation
Editors Tomio Inoue School of Medicine Yokohama City University Yokohama, Japan
David Yang Vyripharm Biopharmaceuticals University of Texas Health Science Center Houston, TX, USA
Gang Huang Renji Hospital / Department of Nuclear Medicine Shanghai Jiao Tong University Shanghai, China
ISBN 978-981-10-3348-3 ISBN 978-981-10-3349-0 (eBook) DOI 10.1007/978-981-10-3349-0 Library of Congress Control Number: 2017931586 © Springer Nature Singapore Pte Ltd. 2017 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer Nature Singapore Pte Ltd. The registered company address is: 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore
Foreword
In the past 40 years, there has been an enormous increase in the range of imaging techniques available to investigate patients with cancer. Imaging modalities including computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, optical imaging, and gamma scintigraphy have been used to diagnose cancer. Although CT and MRI provide considerable anatomic information about the location and the extent of tumors, they do not adequately provide optimal staging and differentiate residual or recurrent tumors from edema, radiation necrosis, or gliosis. Ultrasound images demonstrate local regional abnormalities, but they are operator- dependent. The optical imaging showed promising results; however, its ability to detect deep tissue penetration still has rooms to improve. Radionuclide imaging modalities (positron emission tomography, PET; single photon emission computed tomography, SPECT) are diagnosti
Data Loading...
